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Abstract: Histopathologic determination of tumor regression
provides important prognostic information for locally advanced
gastroesophageal carcinomas after neoadjuvant treatment. Re-
gression grading systems mostly refer to the amount of therapy-
induced ﬁbrosis in relation to residual tumor or the estimated
percentage of residual tumor in relation to the former tumor
site. Although these methods are generally accepted, currently
there is no common standard for reporting tumor regression in
gastroesophageal cancers. We compared the application of these
2 major principles for assessment of tumor regression: hema-
toxylin and eosin–stained slides from 89 resection specimens of
esophageal adenocarcinomas following neoadjuvant chemo-
therapy were independently reviewed by 3 pathologists from
different institutions. Tumor regression was determined by the
5-tiered Mandard system (fibrosis/tumor relation) and the
4-tiered Becker system (residual tumor in %). Interobserver
agreement for the Becker system showed better weighted k
values compared with the Mandard system (0.78 vs. 0.62).
Evaluation of the whole embedded tumor site showed improved
results (Becker: 0.83; Mandard: 0.73) as compared with only 1
representative slide (Becker: 0.68; Mandard: 0.71). Modification
into simplified 3-tiered systems showed comparable interob-
server agreement but better prognostic stratification for both
systems (log rank Becker: P=0.015; Mandard P=0.03), with
independent prognostic impact for overall survival (modified
Becker: P=0.011, hazard ratio=3.07; modified Mandard:
P=0.023, hazard ratio=2.72). In conclusion, both systems
provide substantial to excellent interobserver agreement for
estimation of tumor regression after neoadjuvant chemotherapy
in esophageal adenocarcinomas. A simple 3-tiered system with
the estimation of residual tumor in % (complete regression/1%
to 50% residual tumor/>50% residual tumor) maintains the
highest reproducibility and prognostic value.
Key Words: tumor regression, chemotherapy, interobserver
variability, esophageal adenocarcinoma
(Am J Surg Pathol 2014;38:1551–1556)
Neoadjuvant chemotherapy (CTX) or radio-chemotherapy, followed by surgery or perioperative
treatment, represents the current standard treatment for
locally advanced esophageal adenocarcinomas and ad-
enocarcinomas of the gastroesophageal junction.1,2 This
approach has been shown to provide clinical beneﬁt for
patients compared with surgery alone; particularly pa-
tients with complete or subtotal tumor response show
signiﬁcant improved survival.1–4
The eﬀects of preoperative treatment can be de-
termined by histology, and determination of tumor
regression (ie, tumor regression grading [TRG]) is now
frequently integrated in the pathology reports of resection
specimens for these tumors.5,6 TRG systems for upper
gastrointestinal carcinomas refer to the amount of ther-
apy-induced ﬁbrosis in relation to residual tumor (eg,
Mandard system)7 or the estimated percentage of residual
tumor in relation to the previous tumor site (eg, Becker,
Schneider, or Chirieac system).8–11 Currently, there is no
common standard for processing resection specimens
after neoadjuvant treatment and for subsequent reporting
of tumor regression for gastrointestinal cancer. It is still a
matter of debate which system may provide better results
in terms of interobserver agreement or prognostic value.
In this study, we compared the application of these 2
major approaches for assessment of TRG in esophageal
adenocarcinomas after neoadjuvant CTX especially with
regard to the following: (a) interobserver agreement; (b)
reliability of assessment of TRG on 1 representative slide
or on the whole (previous) tumor area; (c) prognostic
discrimination.
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MATERIALS AND METHODS
Case Selection
Hematoxylin and eosin–stained slides from 89 ran-
domly selected resection specimens out of a collection of
280 cases with locally advanced esophageal ad-
enocarcinomas, following neoadjuvant CTX,12 were used
for this study. The patients were treated between 1996
and 2007 in the department of surgery at Klinikum
Rechts der Isar der Technische Universita¨t Mu¨nchen,
Germany. Neoadjuvant treatment consisted of cisplatin-
based or oxaliplatin-based and 5-fluorouracil-based CTX
(PLF/OLF regime) without additional radiation, ac-
cording to previously published protocols, including the
MUNICON trial. Patients of 60 years or younger and
otherwise good health status were also given paclitaxel
(T-PLF/OLF).13,14 Surgery was conducted 2 to 3 weeks
after CTX completion. The study protocols of neo-
adjuvant CTX were approved by the institutional review
board at the Technische Universita¨t Mu¨nchen. Patient
follow-up assessment was performed every 3 months for
the first year and at 6-month intervals thereafter. The
postoperative pathologic classifications of the tumors used
in this study, which were taken from the original patho-
logic reports are given in Table 1. For comparison, the
description of the whole collection of 280 cases, which has
already been described in previous studies,12,15 is given as a
supplemental file (S1, Supplemental Digital Content 1,
http://links.lww.com/PAS/A215). All resection specimens
had been worked up in a standardized manner, which in-
cluded embedding of the whole tumor bed.8,15
Estimation of Tumor Regression
The slides were reviewed by 3 independent pathol-
ogists (E.K., S.T., R.L.) who were unaware of the initial
pathologic report. TRG was performed according to the
(a) Mandard system,7 which recognizes 5 histologic
TRGs, on the basis of the ratio of vital tumor tissue and
ﬁbrosis: TRG1—complete regression (= fibrosis without
detectable tumor cells); TRG2—fibrosis with scattered
tumor cells; TRG3—fibrosis and tumor cells with pre-
ponderance of fibrosis; TRG4—fibrosis and tumor cells
with preponderance of tumor cells; TRG5—tumor with-
out changes of regression (Table 2A); and (b) Becker
system,8 in which the grading of the tumor regression is
based on the estimation of the percentage of vital tumor
tissue in relationship to the macroscopically identifiable
tumor bed (previous site of the tumor) and is divided into
4 grades: TRG1a—complete tumor regression without
residual tumor; TRG1b—<10% residual tumor per tu-
mor bed; TGR2—10% to 50% residual tumor; TRG3—
>50% residual tumor cells with or without signs of
treatment effect (Table 2B). Histologic examples of dif-
ferent degrees of regression are shown in Figure 1.
For 39 cases, all slides from the completely em-
bedded tumor bed were reviewed. For 50 cases only 1
representative slide was used for estimation of TRG. For
comparative ﬁnal analysis, a deﬁnitive TRG was de-
termined for both systems according to the best interob-
server agreement (see below).
Statistics
For the statistical procedures SAS V9.2 (The SAS
Institute, Cary, NC) and SPSS 21 software (SPSS Inc.,
Chicago, IL) were used. For categorical methods, simple
and weighted k values were used. Estimation of survival
probabilities in patient subgroups by univariate analysis
was performed using the Kaplan-Meier method, and the
log rank test was used for statistical comparisons. Cox
proportional hazard models were used to analyze multi-
variate relationships of covariates with survival. To de-
termine the eﬀect of each variable on patients’ outcome
95% conﬁdence intervals (CI) were used. All tests were 2
sided, and the signiﬁcance level was set at 0.05. To esti-
mate the goodness-of-ﬁt of each TRG, the Akaike
TABLE 1. Histopathologic Characterization of the Case
Collection
Parameter n (%)
ypT category
ypT0 7 (8.0)
ypT1 5 (6.0)
ypT2 18 (20.2)
ypT3 58 (65.2)
ypT4 1 (1.1)
ypN category
ypN0 28 (31.5)
ypN1 17 (19.1)
ypN2 24 (27)
ypN3 20 (22.5)
Distant metastases
Absent 76 (85.4)
Present 13 (14.6)
Diﬀentiation (grading)
G2 32 (36)
G3/G4 53 (59.6)
Resection status
R0 77 (86.5)
R1 12 (13.4)
TRG original report (Becker)
TRG1a 7 (7.9)
TRG1b 16 (18)
TRG2 21 (23.6)
TRG3 45 (50.6)
Total 89 (100)
TABLE 2. TRG Systems Used in This Study
TRG Criteria
(A) Mandard TRG System
1 Complete regression (=ﬁbrosis without detectable tissue of
tumor)
2 Fibrosis with scattered tumor cells
3 Fibrosis and tumor cells with preponderance of ﬁbrosis
4 Fibrosis and tumor cells with preponderance of tumor cells
5 Tissue of tumor without changes of regression
(B) Becker TRG System
1a No residual tumor/tumor bed+CTX eﬀect
1b <10% residual tumor/tumor bed+CTX eﬀect
2 10%-50% residual tumor/tumor bed+CTX eﬀect
3 >50% residual tumor/tumor bed+CTX eﬀect
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Information Criterion (AIC) and Schwarz Bayesian
Information Criterion (SBC) were used. Both methods
adjust the 2 log likelihood statistics for the number of
parameters in the model and the number of observations
used. Lower values of AIC and SBC indicate superior
model ﬁt, with the “best” model showing the lowest val-
ues for both.
RESULTS
Scoring Results
For the 3 participants the concordance rates were
58.4%, 56.2%, and 38.2% (mean 50.9%) for the
Mandard TRG system and 69.7%, 83.1%, and 77.5%
(mean 76.7%) for the Becker TRG system. When ana-
lyzing the whole tumor bed the rates were 71.8%, 59.0%,
and 53.8% (mean 61.3%) for the Mandard system and
87.0%, 76.9%, and 74.0% (mean 79.3%%) for the
Becker system; when using only 1 representative slide for
TRG estimation the rates were 58.0%, 44.0%, and 26.0%
(mean 42.7%) for the Mandard system and 80.0%,
78.0%, and 60.0% (mean 72.7%) for the Becker system.
The tables with the comparison of the participants are
given in detail as supplemental ﬁles (S2, Supplemental
Digital Content 2, http://links.lww.com/PAS/A216). The
comparison of the deﬁnitive TRGs determined as de-
scribed above showed a highly signiﬁcant correlation
between the Mandard and the Becker score (w2<0.001);
however, there were some discrepancies in the
“intermediate” TRGs Mandard 2 to 4 and Becker 1b and
2 (Table 3). The concordance rate of the consent TRG
and the TRG of the initial report was 82% (73/89).
Interobserver Agreement
Overall, average interobserver agreement for the
5-tiered Mandard system was 0.36 (k) and 0.62 (weighted
k). For the 4-tiered Becker system it was 0.64 (k) and 0.78
(weighted k). Evaluation of the whole embedded tumor
site showed improved results (Becker: k=0.72/weighted
k=0.83; Mandard: 0.51/0.73) as compared with only 1
representative slide (Becker: 0.55/0.68; Mandard: 0.21/
0.49). The results of these analyses are given in detail as
supplemental ﬁles (S3, Supplemental Digital Content 3,
http://links.lww.com/PAS/A217).
Modification Into 3-Tiered Systems
Following the data of our own ﬁndings and of
others regarding the prognostic impact of a simpliﬁed
3-tiered TRG,15,16 we performed a separate analysis with
both methods of estimation of TRG modiﬁed into
FIGURE 1. Histologic examples of different grades of tumor regression of esophageal adenocarcinomas following neoadjuvant
CTX: (A) complete regression; (B) subtotal/partial tumor regression with < 50% residual tumor; (C) no regression with >50%
residual tumor (hematoxylin and eosin staining).
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3-tiered systems (for Mandard: TRG1 vs. TRG2+TRG3
vs. TRG4+TRG5; for Becker: TRG1a vs. TRG1b+
TRG2 vs. TRG3). This resulted in improved concordance
rates, with 85.4%, 76.4%, and 70.8% (mean 77.5%) for
the modiﬁed Mandard system and 88.8%, 86.5%, and
78.7% (mean 84.7%) for the modiﬁed Becker system
(S1, Supplemental Digital Content 1, http://links.lww.
com/PAS/A215). Average interobserver agreement was
also enhanced for both systems: for the modiﬁed Man-
dard system it was k=0.61/weighted k=0.67; for the
modiﬁed Becker system it was k=0.74/weighted
k=0.77 (S3, Supplemental Digital Content 3, http://
links.lww.com/PAS/A217).
Survival Analysis
For survival analysis, the deﬁnitive TRGs for both
systems were determined according to the best interob-
server agreement. Both systems had prognostic impact for
overall survival (log rank Becker: P=0.047; log rank
Mandard: P=0.053). The modiﬁed 3-tiered TRGs
showed superior prognostic stratiﬁcation for both sys-
tems (log rank modiﬁed Becker: P=0.015; log rank
modiﬁed Mandard: P=0.03; Fig. 2). Other prognostic
relevant factors in univariate analysis were ypT category
(P=0.003), ypN category (P=0.001), distant metastases
(P=0.001), tumor diﬀerentiation (grading, P=0.004),
and resection status (P<0.001). The modiﬁed TRGs, but
not the original 5-tiered or 4-tiered scores were also in-
dependent prognostic factors for overall survival in this
case collection (modiﬁed Becker: P=0.011, hazard ra-
tio=3.07 [95% CI, 1.3-7.3]; modiﬁed Mandard:
P=0.023, hazard ratio=2.72 [95% CI, 1.5-6.4];
Table 4). The AIC and BIC values of the 2 systems were
comparable (modiﬁed Mandard: 222/227; modiﬁed
Becker: 222/226).
DISCUSSION
Histopathologic TRG has been shown to provide
important prognostic information for patients with
locally advanced gastroesophageal carcinomas after pre-
operative CTX. Whereas for gastric and rectal cancers
data about an independent prognostic impact of TRG are
divergent,17–20 the most consistent reports have been
published on esophageal carcinomas. In various studies it
has been shown that TRG and lymph node statuses are
the most important prognostic factors for both ad-
enocarcinoma and squamous cell carcinomas.4,15,16 This
led to proposals of alternative staging systems and the
suggestion for the implementation of TRG into the
forthcoming AJCC/UICC staging system by several au-
thors.10–12,16,21
In the present study we investigated the 2 main
approaches for estimation of tumor regression by using 2
commonly used TRG systems as examples. One concept
of grading of tumor regression is the estimation of the
amount of residual tumor in correlation to ﬁbrosis—often
in a descriptive manner, such as the Mandard system.7
Other TRG systems, such as the Becker grading system,8
TABLE 3. Comparison Between TRGs (Consent) According to
Mandard and Becker (w2 < 0.001)
TRG According to Becker
1a 1b 2 3 Total
TRG according to Mandard
1 7 0 0 0 7
2 0 12 2 0 14
3 0 2 13 3 18
4 0 0 6 36 42
5 0 0 0 8 8
Total 7 14 21 47 89
FIGURE 2. Survival analysis: (A) modified TRG according to Mandard, 3-tiered (see also Donohoe et al16); (B) modified TRG
according to Becker, 3-tiered (see also Chirieac et al4 and Langer et al15).
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which was used in this study, as well as the Chirieac,4
Schneider,9 or Rizk11 systems, use the percentage of re-
sidual tumor in the previous tumor site (the tumor bed) as
basis for the TRG. In line with other authors,22,23 we
could demonstrate that both concepts provided sub-
stantial to excellent interobserver agreement for the esti-
mation of tumor regression after neoadjuvant CTX and
radiochemotherapy in esophageal cancers. In these pre-
vious studies, however, only 1 single system has been in-
vestigated. Only Mirza et al24 compared 2 different
grading systems case by case (for gastric carcinomas and
adenocarcinomas of the gastroesophageal junction), and
in agreement with our findings they reported comparable
results with substantial interobserver agreement for both
systems and a slight advantage of the percentage-based
estimation of tumor regression.
A reason for the higher rate of disagreement for the
Mandard score may be the existence of diﬃculties in the
assessment of the relative amount of ﬁbrosis. This has
been debated to show lack of reproducibility in a recent
work by Chetty et al,25 who investigated the level of in-
terobserver agreement among expert gastrointestinal
pathologists for TRG in rectal cancer following neo-
adjuvant radiochemotherapy. In this study, 17 patholo-
gists applied various regression grading systems for
gastrointestinal cancers (eg, the Mandard7 or the TRG
according to the Royal College of Pathologists26) on se-
lected slides of tumors, which resulted in unsatisfactory
interobserver agreement for all TRG systems. The au-
thors of this paper concluded that there was a need for a
simple, reproducible regression grading system with clear
criteria and a standardized workup of the resection
specimen favoring the assessment of the complete tumor
bed as basis for the estimation of TRG. The results of our
study conﬁrm these suggestions as we could demonstrate
a better interobserver agreement for the cases in which the
whole tumor bed was evaluated in multiple slides, in
contrast to the subgroup of cases in which only 1 selected
slide was analyzed. Moreover, we could show that a
modiﬁcation of both the 5-tiered Mandard score and the
4-tiered Becker score not only resulted in statistically
superior rates for interobserver agreement (eg, there were
disagreements for the distinction of Mandard score 2 and
3, and 4 and 5, which were then merged to 1 TRG in the
modiﬁed system) but also in achievement of a better
prognostic impact of TRG. In previous studies we already
have used a modiﬁed Becker score, which originally was
developed for gastric cancer and which has been applied
for TRG in esophageal cancers in our institute as well.15
By correlation of the TRGs with clinical outcome we
could demonstrate that in the large cohort of esophageal
adenocarcinomas from the Technische Universita¨t
Munich, from which the cases of the present study had
been randomly selected, a 3-tiered TRG (complete
regression—partial regression; ie, <50% residual tumor
and no regression) shows improved prognostic value over
the original Becker score with 4 grades.12,15 In contrast to
gastric cancer,27 there is evidence that even small tumor
residuals are associated with a more unfavorable out-
come, comparable to the prognosis for partial tumor re-
gression (ie, Becker grade 2; 10% to 50% residual tumor).
Therefore, a 3-tiered TRG may not only show better in-
terobserver agreement but also enhanced prognostication
in clinical management. Similar observations have been
made by others,5,23 and recently, Donohoe et al16 de-
scribed the superiority of an identically modified
Mandard score over the original 5-tiered grading system
and showed an improved prognostic value of this 3-tiered
system compared with other commonly used TRGs in a
comprehensive study on a large number of cases. In
contrast to our study, however, the TRG systems, which
were compared with the modified Mandard system in this
study, had not been modified or simplified, and the
comparison was not done by reviewing the slides of the
cases but by a retrospective analysis of the histopatho-
logic reports in the majority of cases. We consider our
approach of case-by-case comparison and TRG estima-
tion by 3 independent pathologists as a major strength of
our study. In contrast to other works with similar study
design,23,25 we did not invite external pathologists for
participation. The 3 investigators in our study, however,
have been trained and working in different locations be-
fore joining the current affiliation. The study was con-
ducted within the first year at the new institute so a
significant in-house bias should be unlikely.
In summary, we could demonstrate that both
principles—estimation of the relation of fibrosis to re-
sidual tumor versus residual tumor in %—for the as-
sessment of tumor regression after neoadjuvant treatment
in esophageal adenocarcinomas provide substantial to
excellent interobserver agreement, with a slight superi-
ority of the “residual tumor %”–based TRG system. It is
noteworthy that TRG should be assessed after histologic
evaluation of the whole embedded tumor bed and not of 1
representative slide. In line with previous published
studies,23 a simplified 3-tiered system (complete re-
gression/1% to 50% residual tumor/>50% residual tu-
mor) shows the best reproducibility and prognostic value.
TRG according to this system can be recommended to be
part of every standard pathology report of esophageal
adenocarcinomas following neoadjuvant treatment.
TABLE 4. Multivariate Analysis for Overall Survival
Parameter HR 95% CI P
Including modiﬁed Mandard score
ypT category 1.87 0.84-4.15 0.12
ypN category 1.48 1.06-2.08 0.02
Distant metastases 2.18 0.75-6.35 0.15
Diﬀerentiation 1.31 0.65-2.61 0.45
Resection status 1.51 0.62-3.68 0.37
TRG (modiﬁed Mandard) 2.72 1.15-6.44 0.02
Including modiﬁed Becker score
ypT category 1.887 0.854-4.17 0.12
ypN category 1.517 1.08-2.132 0.02
Distant metastases 2.372 0.792-7.104 0.12
Diﬀerentiation 1.197 0.584-2.454 0.62
Resection status 1.412 0.565-3.532 0.46
TRG (modiﬁed Becker) 3.071 1.286-7.33 0.01
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